Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.

The European IPF registry (eurIPFreg): baseline characteristics and survival of patients with idiopathic pulmonary fibrosis

Open access

Abstract

BACKGROUND: Since 2009, IPF patients across Europe are recruited into the eurIPFreg, providing epidemiological data and biomaterials for translational research. METHODS: The registry data are based on patient and physician baseline and follow-up questionnaires, comprising 1700 parameters. The mid- to long-term objectives of the registry are to provide clues for a better understanding of IPF phenotype sub-clusters, triggering factors and aggravating conditions, regional and environmental characteristics, and of disease behavior and management. RESULTS: This paper describes baseline data of 525 IPF subjects recruited from 11/2009 until 10/2016. IPF patients had a mean age of 68.1 years, and seeked medical advice due to insidious dyspnea (90.1%), fatigue (69.2%), and dry coughing (53.2%). A surgical lung biopsy was performed in 32% in 2009, but in only 8% of the cases in 2016, possibly due to increased numbers of cryobiopsy. At the time of inclusion in the eurIPFreg, FVC was 68.4% ± 22.6% of predicted value, DLco ranged at 42.1% ± 17.8% of predicted value (mean value ± SD). Signs of pulmonary hypertension were found in 16.8%. Steroids, immunosuppressants and N-Acetylcysteine declined since 2009, and were replaced by antifibrotics, under which patients showed improved survival (p = 0.001). CONCLUSIONS: Our data provide important insights into baseline characteristics, diagnostic and management changes as well as outcome data in European IPF patients over time. TRIAL REGISTRATION: The eurIPFreg and eurIPFbank are listed in ClinicalTrials.gov( NCT02951416 ).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12931-018-0845-5

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Distribution and diversity of ILD diagnoses in the eurIPFreg cohort. Data are presented as patients numbers per diagnosis. IBD: inflammatory bowel diseases; DPLD: diffuse parenchymal lung diseases
Fig. 1 Distribution and diversity of ILD diagnoses in the eurIPFreg cohort. Data are presented as patients numbers per diagnosis. IBD: inflammatory bowel diseases; DPLD: diffuse parenchymal lung diseasesCC BY · PubMed Central
Fig. 2 Distribution of self-reported symptoms of IPF patients. Data are presented as percentage of all patients with reported symptom
Fig. 2 Distribution of self-reported symptoms of IPF patients. Data are presented as percentage of all patients with reported symptomCC BY · PubMed Central
Fig. 3 Change in biopsy procedures in IPF over time. Data are given as percentage of the respective procedure undertaken in IPF subjects in the year of first diagnosis
Fig. 3 Change in biopsy procedures in IPF over time. Data are given as percentage of the respective procedure undertaken in IPF subjects in the year of first diagnosisCC BY · PubMed Central
Fig. 4 Spectrum of co-morbidities in the IPF cohort. Data are given as percentage of all patients. Multiple co-morbidities could be reported
Fig. 4 Spectrum of co-morbidities in the IPF cohort. Data are given as percentage of all patients. Multiple co-morbidities could be reportedCC BY · PubMed Central
Fig. 5 Change in IPF treatment over time. The graph shows various therapeutic regime (acetylcysteine, azathioprine, prednisolone, mycophenolic acid and anti-fibrotic drugs) in percentage of all treated patients
Fig. 5 Change in IPF treatment over time. The graph shows various therapeutic regime (acetylcysteine, azathioprine, prednisolone, mycophenolic acid and anti-fibrotic drugs) in percentage of all treated patientsCC BY · PubMed Central
Fig. 6 Overall survival of IPF patients upon first diagnosis depending on treatment. Given are Kaplan-Meier curves for cumulative survival, based on definite outcome data (survival status definitely known as per end of 2016) and on last visit data. A statistically significant difference in survival was encountered between patients receiving anti-fibrotic treatment and those not receiving antifibrotics, significance level p was 0.001. Within the group of patients receiving antifibrotic treatment, 83% of patients received pirfenidone and 17% received nintedanib
Fig. 6 Overall survival of IPF patients upon first diagnosis depending on treatment. Given are Kaplan-Meier curves for cumulative survival, based on definite outcome data (survival status definitely known as per end of 2016) and on last visit data. A statistically significant difference in survival was encountered between patients receiving anti-fibrotic treatment and those not receiving antifibrotics, significance level p was 0.001. Within the group of patients receiving antifibrotic treatment, 83% of patients received pirfenidone and 17% received nintedanibCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 40 references

Cited by

See all 291

Metadata

Authors
Guenther, A., Krauss, E., Tello, S., Wagner, J., Paul, B., Kuhn, S., Maurer, O., Heinemann, S., Costabel, U., Barbero, M. A. N., Müller, V., Bonniaud, P., Vancheri, C., Wells, A., Vasakova, M., Pesci, A., Sofia, M., Klepetko, W., Seeger, W., Drakopanagiotakis, F., & Crestani, B.
Affiliations
  • Justus-Liebig-Universität Gießen (DE)
  • Ruhrlandklinik (DE)
  • Hospital Clínico San Carlos (ES)
  • Semmelweis University (HU)
  • Université de Bourgogne (FR)
  • University of Catania (IT)
  • Royal Brompton Hospital (GB)
  • Azienda Ospedaliera San Gerardo (IT)
  • University of Naples Federico II (IT)
  • Medical University of Vienna (AT)
  • Goethe University Frankfurt (DE)
  • Hôpital Bichat-Claude-Bernard (FR)
Venue
Respiratory Research
Published
2018-07-28
Volume
19
Issue
1
Pages
141-141
ISSN
  • 1465-9921 (ISSN-L)
  • 1465-993X
OpenAlex
W2883908584
Cited by
268
References
40
Citations by year
2026: 21 · 2025: 17 · 2024: 18 · 2023: 38 · 2022: 42 · 2021: 48 · 2020: 41 · 2019: 40 · 2018: 3
FWCI
24.84
Type
journal article
Language
en
Open access
Licence
  • cc-by
  • creativecommons.org/licenses/by/4.0/ (tdm)
Locations
  • Respiratory Research (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • HAL (submittedVersion)
  • BOA (University of Milano-Bicocca) (submittedVersion, other-oa)
  • LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • University writing server of the Justus Liebig University Giessen (Justus-Liebig-Universität Gießen) (submittedVersion, cc-by)
  • Publication Server of Goethe University Frankfurt am Main (Goethe University Frankfurt) (submittedVersion, cc-by)
  • Zenodo (CERN European Organization for Nuclear Research) (submittedVersion, cc-by)
  • Universitätsbibliothek Gießen (cc-by)
Funders
European IPF Network FP7 Program
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
Keywords
idiopathic pulmonary fibrosis, patient registry, survival, antifibrotic therapy, lung function, pulmonary hypertension, corticosteroids, immunosuppressants, N-acetylcysteine, open lung biopsy, cryobiopsy, dyspnea
MeSH terms
Aged, Aged, 80 and over, Biopsy, Europe, Female, Humans, Longitudinal Studies, Lung, Male, Registries, Cohort Studies, Survival Rate, Idiopathic Pulmonary Fibrosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The European IPF registry (eurIPFreg): baseline characteristics and survival of patients with idiopathic pulmonary fibrosis. https://app.cochat.ai/papers/10.1186/s12931-018-0845-5
The paper
Guenther, A., Krauss, E., Tello, S., Wagner, J., Paul, B., Kuhn, S., Maurer, O., Heinemann, S., Costabel, U., Barbero, M. A. N., Müller, V., Bonniaud, P., Vancheri, C., Wells, A., Vasakova, M., Pesci, A., Sofia, M., Klepetko, W., Seeger, W., . . . Crestani, B. (2018). The European IPF registry (eurIPFreg): baseline characteristics and survival of patients with idiopathic pulmonary fibrosis. Respiratory Research. https://doi.org/10.1186/s12931-018-0845-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.